The generation of solid tumor targeting domains specific to cancer cells remains a significant challenge in the biopharmaceutical industry. GO Therapeutics’ targeting platforms and technologies hold the promise to unlock the full potential of antibody-drug conjugates, bi-specific T-cell engagers, and immune-based cell therapies.
